Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

Press/Media: Press / Media

PeriodDec 7 2019 → Dec 8 2019

Media coverage

26

Media coverage

  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletBiotechgate
    CountrySwitzerland
    Date12/8/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletCanadian Life Sciences Database
    CountrySwitzerland
    Date12/8/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletPR Newswire
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletCanada NewsWire
    CountryCanada
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    CountryJordan
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletPR Newswire
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletCanada NewsWire
    CountryCanada
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletPR Newswire
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletMorningstar.com
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletIndia Pharma News
    CountryIndia
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletFinanzen.ch
    CountrySwitzerland
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletStocksNewsFeed.com
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSIERRA ONCOLOGY : Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletMarketScreener.com
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion R
    Media name/outletADVFN Deutschland
    CountryGermany
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletTickerTech.com
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletMarkets Business Insider
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletSpoke.com
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletCrwe World
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • Title$SRRA Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletOTC Dynamics
    CountryCanada
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly...
    Media name/outletEpicos.com
    CountryGreece
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletProfitQuotes.com
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletChannel 8 Eyewitness News
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletErie News Now
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletWICZ
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletVB Profiles
    CountryUnited States
    Date12/7/19
    PersonsRuben Mesa
  • TitleSierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
    Media name/outletCentral Charts
    CountryFrance
    Date12/7/19
    PersonsRuben Mesa